<DOC>
	<DOCNO>NCT01211704</DOCNO>
	<brief_summary>The primary specific aim examine efficacy Paliperidone extend release Paliperidone Palmitate Injection ( INVEGA® SUSTENNA™ ) compare placebo decrease manic symptom patient comorbid DSM-IV bipolar disorder alcohol dependence . The investigator hypothesize Paliperidone Palmitate Injection ( INVEGA® SUSTENNA™ ) treat group statistically significant advantage improvement manic symptom . They also higher rate treatment response remission .</brief_summary>
	<brief_title>Paliperidone Palmitate Efficacy Safety Bipolar Disorder Complicated Alcoholism</brief_title>
	<detailed_description>Subjects meet study inclusion criterion randomize receive add-on Paliperidone Palmitate ( INVEGA® SUSTENNA™ ) accord follow schedule describe medication prescribe information : INVEGA® SUSTENNA™ ( PALIPERIDONE PALMITATE ) Extended-Release Injectable Suspension ) . Tolerability paliperidone establish either 1 ) document history take either paliperidone risperidone past without untoward effect allergic reaction , 2 ) prescribe oral paliperidone 6mg per day three day absence allergic severe untoward side effect prior history take medication , prior initiate treatment INVEGA® SUSTENNA™ accord manufacturer ' recommendation . Eligible patient randomize INVEGA® SUSTENNA™ placebo equivalent ml dos accord follow schedule : Day 1 : INVEGA® SUSTENNA™ 234mg vs. placebo injection ( equivalent ml ) ; Day 8 ( week 1 ) INVEGA® SUSTENNA™ 156mg vs. placebo injection ( equivalent ml ) ; Day 36 ( week 5 ) : INVEGA® SUSTENNA™ 117 mg vs. placebo injection ( equivalent ml ) ( latter dose could range 39mg 156mg accord tolerability clinical symptom bipolar disorder ) ; Day 64 ( week 9 ) injection ; week 10 11 safety assessment follow-up ( see Study Schematics ) . Both treatment group participate standardize individual medication adherence counseling . Subjects bipolar disorder actively drink recruit study . Subjects stable treatment usual medication bipolar disorder least three week , meet inclusion criterion randomize receive double blind study medication consistent either Paliperidone Palmitate injection ( INVEGA® SUSTENNA™ ) placebo ( 1:1 ratio ) . To optimize likelihood balance group , investigator use urn randomization follow variable : Gender ( male vs. female ) , treatment usual medication ( divalproex sodium vs. mood stabilizer ) , present bipolar subtype ( manic v mixed ) baseline drink severity ( &lt; vs. &gt; 50 % heavy drinking day ( &gt; 4 standard drink female &gt; 5 standard drink per male ) month prior enrollment ) . After randomization , subject assess weekly week 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8,9 double-blind treatment phase week 10 11 safety observation follow-up.. The investigator propose test hypotheses 75 subject three site ( 25 subject per site ) All subject receive weekly Standardized supportive individual medication adherence counsel session .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients assess use Mini International Neuropsychiatric Interview baseline , carry least three day acute withdrawal symptom clear . Subjects meet DSMIV criterion alcohol use disorder ( abuse dependence ) concurrent bipolar I disorder , ( Mixed Mania State ) score YMRS 16 , without exclusion criterion recruit study . The following criterion must meet . A ) Abstinent alcohol exceed 21 consecutive day , score &lt; 8 CIWAAr , [ Sullivan , 1989 # 1412 ] time randomization . B ) An average minimum &gt; 7 drink per week female &gt; 14 drink per week male , consecutive 4week period 12week period prior baseline . C ) A breath alcohol concentration ( BAC ) 0 time signing Informed Consent . D ) Subject stable treatment usual medication bipolar disorder least three week prior randomization . Patients follow disorder exclude study : 1 ) Schizophrenia , schizoaffective , nonbipolar psychotic disorder , unipolar major depression , primary anxiety disorder , mental retardation , sign impair cognitive functioning ( operationalized score &lt; 25 Folstein 's MiniMental Status Exam ) . [ Folstein , 1975 # 1179 ] . 2 ) Current DSMIV criterion dependence substance alcohol , cannabis , nicotine , caffeine . 3 ) Neurological condition include epilepsy , history brain injury , encephalitis , organic brain syndrome document focally abnormal electroencephalograph examination ( EEG ) , recent history ( within past two year ) alcohol withdrawal seizure . 4 ) Medical condition include severe cardiac , liver , kidney , endocrine ( e.g . diabetes ) , hematologic ( e.g . porphyria bleed abnormality ) , impair medical condition , impend surgery . 5 ) Congenital prolongation QT interval ( congenital long QT syndrome ) , history cardiac arrhythmia condition prolong QT interval bradycardia ; hypokalemia hypomagnesemia ; concomitant medication know prolong QTc include Class 1A ( e.g. , quinidine , procainamide ) Class III ( e.g. , amiodarone , sotalol ) antiarrhythmic medication , antipsychotic medication ( e.g. , chlorpromazine , thioridazine ) , antibiotic ( e.g. , gatifloxacin , moxifloxacin ) , class medication know prolong QTc interval . 6 ) Persistent elevation liver function enzymes indicate active liver disease ( elevated t. bilirubin &gt; 1.5 mg/dl , elevation threetime normal range liver enzyme , SGOT , SGPT , gGTP ) . 7 ) Any medication effective alcohol dependence disulfiram , naltrexone , acamprosate , topiramate . Carbamazepine potential clinically significant drugdrug interaction . Other exclusion criterion include pregnancy , woman breastfeed , inability unwillingness use contraceptive method , inability read understand study form agree informed consent , base judgment investigative team study may best interest subject either due additional safety concern factor may interfere study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Bipolar , Alcoholism</keyword>
</DOC>